All In Biotech

Drug Trial Radar · NCT07389044

A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Feb 20, 2026

Primary completion

Apr 30, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
IntegerBioIndustry
Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). A separate exploratory, open-label, single-dose cohort (Part C) will evaluate pegylated interferon alfa-2a in HVs for translational benchmarking against IB-001.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

  • IB-001Drug

    IB-001 is an investigational product targeting the type I IFN (IFN-I) signaling pathway. Subcutaneous (SC) injectable formulation; single doses in HVs (Part A) and weekly doses for 4 weeks in CHB participants (Part B). Exact dose levels recommended by SRC.

  • PlaceboOther

    Sodium Chloride (NaCl) 0.9 % administered subcutaneously as a single dose (Part A) and weekly dose for 4 weeks (Part B).

  • Peginterferon Alfa-2ADrug

    Peginterferon alfa-2a administered subcutaneously as a single dose (Part C) at a dose of 180 mcg/0.5 mL solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs).Time frame: Through Day 29 (Part A), through Day 64 (Part B).
  2. Part A and Part B: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Through Day 29 (Part A), through Day 64 (Part B)
  3. Part A and Part B: Number of Participants with Adverse Events (AEs) of Special Interest (AESIs)Time frame: Through Day 29 (Part A), through Day 64 (Part B)
  4. Part A and Part B: Number of Participants with Clinically Significant Changes in Laboratory ParametersTime frame: Through Day 15 (Part A), through Day 64 (Part B)
  5. Part A and Part B: Number of Participants with Clinically Significant Changes in Vital Signs.Time frame: Through Day 15 (Part A), through Day 64 (Part B)
  6. Part A and Part B: Number of Patients with Clinically Significant Changes in Cardiac Parameters.Time frame: Through Day 15 (Part A), through Day 64 (Part B)

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • Arensia Exploratory Medicine Chisinau

    Chisinau, Moldova · Recruiting

  • New Zealand Clinical Research

    Auckland, Auckland, New Zealand · Recruiting

  • Arensia Exploratory Medicine

    Kyiv, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.